AR080736A1 - Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla - Google Patents
Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararlaInfo
- Publication number
- AR080736A1 AR080736A1 ARP110101023A ARP110101023A AR080736A1 AR 080736 A1 AR080736 A1 AR 080736A1 AR P110101023 A ARP110101023 A AR P110101023A AR P110101023 A ARP110101023 A AR P110101023A AR 080736 A1 AR080736 A1 AR 080736A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- composition according
- active ingredient
- usefully
- diverse
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 10
- 238000004090 dissolution Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 6
- 229920001202 Inulin Polymers 0.000 abstract 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 5
- 229940029339 inulin Drugs 0.000 abstract 5
- 239000011159 matrix material Substances 0.000 abstract 5
- 239000002904 solvent Substances 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical group C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 229960002845 desmopressin acetate Drugs 0.000 abstract 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical group NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001596 famotidine Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical group C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 abstract 1
- 229960003088 loratadine Drugs 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 238000000859 sublimation Methods 0.000 abstract 1
- 230000008022 sublimation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5062—Inulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composicion farmacéutica que comprende una red de matriz abierta que transporta un ingrediente activo farmacéuticamente, en donde la red de matriz abierta comprende inulina. Reivindicacion 4: Una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-3, en donde la matriz comprende inulina y manitol. Reivindicacion 5: Una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-3, en donde la matriz comprende inulina y trehalosa. Reivindicacion 6: Una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-3, en donde la matriz comprende inulina y rafinosa. Reivindicacion 12: Una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-11, en donde el ingrediente activo es acetato de desmopresina. Reivindicacion 13: Una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-11, en donde el ingrediente activo es loratidina. Reivindicacion 14: Una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-1, en donde el ingrediente activo es famotidina. Reivindicacion 15: Una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-11, en donde el ingrediente activo es montelucast sodico. Reivindicacion 16: Un proceso para preparar una composicion farmacéutica que comprende sublimacion de un solvente de una preparacion líquida que comprende un ingrediente activo farmacéuticamente e inulina en el solvente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN742DE2010 | 2010-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080736A1 true AR080736A1 (es) | 2012-05-02 |
Family
ID=54241475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101023A AR080736A1 (es) | 2010-03-29 | 2011-03-29 | Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10086078B2 (es) |
| EP (1) | EP2552403B1 (es) |
| JP (1) | JP5907945B2 (es) |
| KR (1) | KR101725173B1 (es) |
| CN (1) | CN102821755A (es) |
| AR (1) | AR080736A1 (es) |
| AU (1) | AU2011234636B2 (es) |
| BR (1) | BR112012024428A2 (es) |
| CA (1) | CA2793405A1 (es) |
| DK (1) | DK2552403T3 (es) |
| ES (1) | ES2553568T3 (es) |
| HU (1) | HUE026213T2 (es) |
| IL (1) | IL222086A (es) |
| JO (1) | JO3112B1 (es) |
| MX (1) | MX2012011204A (es) |
| NZ (1) | NZ602441A (es) |
| PL (1) | PL2552403T3 (es) |
| PT (1) | PT2552403E (es) |
| RU (1) | RU2566270C2 (es) |
| SA (1) | SA111320317B1 (es) |
| TW (1) | TWI513477B (es) |
| WO (1) | WO2011120903A2 (es) |
| ZA (1) | ZA201207176B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186426B2 (en) | 2009-10-30 | 2025-01-07 | Ix Biopharma Ltd. | Solid dosage form |
| CN107811980B (zh) | 2009-10-30 | 2021-06-18 | Ix 生物医药有限公司 | 快速溶解固体剂型 |
| JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| BR112014005134A2 (pt) * | 2011-09-16 | 2017-04-18 | Ferring Bv | composição farmacêutica de dissolução rápida |
| TW201422254A (zh) | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| US9717684B2 (en) | 2014-04-25 | 2017-08-01 | R.P. Scherer Technologies, Llc | Stable montelukast solution |
| BR112019010949A2 (pt) | 2017-01-11 | 2019-10-01 | Ferring Bv | composição farmacêutica de desintegração rápida |
| CN111904936B (zh) * | 2020-08-28 | 2022-07-19 | 开封康诺药业有限公司 | 一种法莫替丁冻干粉针剂 |
| US20230346695A1 (en) | 2020-09-29 | 2023-11-02 | Millicent Pharma Limited | Orodispersible formulations |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| US20240000808A1 (en) | 2020-11-16 | 2024-01-04 | Orcosa Inc. | Improved use of cannabinoids in the treatment of alzheimer's disease |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA251629A (en) | 1925-07-14 | T. Hanna William | Coal cutting knife | |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| CA1114812A (en) | 1977-08-16 | 1981-12-22 | Carlos Moreno | Hapten polysaccharide conjugates |
| CN1053808C (zh) | 1993-04-24 | 2000-06-28 | 章修纲 | 尼非地平控释剂型 |
| EP0879600A1 (en) | 1997-05-20 | 1998-11-25 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Fructan containing composition for the prevention and treatment of colon cancer |
| EP0958825A1 (en) * | 1998-05-18 | 1999-11-24 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer |
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| WO2000025754A2 (en) | 1998-11-04 | 2000-05-11 | Mcneil-Ppc, Inc. | Solid oral dosage forms containing alginic acid and famotidine |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| NL1012300C2 (nl) * | 1999-06-11 | 2000-12-12 | Rijksuniversiteit | Stabilisator voor farmaca. |
| EP1064938A1 (en) | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| JP2003506480A (ja) * | 1999-08-17 | 2003-02-18 | ノバルテイス・コンシユーマー・ヘルス・エス・アー | 急速に溶解する剤形およびその製造方法 |
| WO2002003992A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating prosthesis-related bone degeneration |
| CN1556712A (zh) | 2000-07-13 | 2004-12-22 | ��һ��������ҩ��ʽ���� | 含dds化合物的药用组合物 |
| IT1319664B1 (it) * | 2000-11-17 | 2003-10-23 | Pharma Biotech Ltd | Addotti di antibatterici chinolonici con polimeri polisaccaridicinaturali. |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| PL209134B1 (pl) * | 2002-04-03 | 2011-07-29 | Solvay Pharm Bv | Sposób wytwarzania kompozycji farmaceutycznej zawierającej naturalny związek kanabinoidowy i kompozycja farmaceutyczna otrzymywana tym sposobem |
| PT1501534E (pt) | 2002-05-07 | 2006-09-29 | Ferring Bv | Formulacoes farmaceuticas |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| WO2003099040A1 (en) * | 2002-05-27 | 2003-12-04 | Advance Holdings Limited | Dietary supplements from wine vinasses and relevant production process |
| US20040096569A1 (en) | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| KR101136573B1 (ko) | 2003-02-28 | 2012-04-23 | 알크-아벨로 에이/에스 | 당류 매트릭스를 갖는 제형 |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| ATE387207T1 (de) | 2003-09-05 | 2008-03-15 | Myung-Jun Chung | Zweifach coating-beschichteten milchsäurenbakterienpulver mit protein und polysaccharid und das verfahren zur deren herstellung sowie deren dosisform |
| CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科（北京）研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
| EP1597978A1 (en) | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| US20060088593A1 (en) | 2004-10-27 | 2006-04-27 | Bunick Frank J | Dosage forms having a microreliefed surface and methods and apparatus for their production |
| TW200621310A (en) * | 2004-11-10 | 2006-07-01 | Univ Groningen | A process for preparing formulations of lypophilic active substances by spray freeze drying |
| CN100339081C (zh) * | 2004-11-10 | 2007-09-26 | 范敏华 | 一种氯雷他定口腔崩解片剂的制备方法 |
| BRPI0519212A2 (pt) * | 2004-12-23 | 2009-01-06 | Mcneil Ppc Inc | composiÇÕes farmacÊuticas de desintegraÇço oral contendo agentes de manifestaÇço sensorial |
| US20070042023A1 (en) | 2005-08-22 | 2007-02-22 | National Starch And Chemical Investment Holding Corporation | Dissolvable film |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| EP2347774B1 (en) | 2005-12-13 | 2017-07-26 | The President and Fellows of Harvard College | Scaffolds for cell transplantation |
| US20070293582A1 (en) | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
| FR2910812B1 (fr) * | 2006-12-29 | 2009-03-20 | Pierre Fabre Medicament Sa | Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante |
| JP2010522246A (ja) | 2007-03-27 | 2010-07-01 | ザ プロクター アンド ギャンブル カンパニー | プロバイオティクスを投与するための方法及びキット |
| EP2170282A4 (en) | 2007-06-27 | 2014-11-05 | Hanmi Pharm Ind Co Ltd | METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION |
| KR100930427B1 (ko) | 2008-01-25 | 2009-12-08 | 정명준 | 3중 코팅 유산균의 제조방법 및 나노 입자 코팅 방법, 그방법으로 제조된 3중 코팅 유산균 및 이를 포함하는 제품 |
| US8623401B2 (en) | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
| JP2012500643A (ja) * | 2008-08-28 | 2012-01-12 | セーホーエル．ハンセン アクティーゼルスカブ | 細菌組成物 |
| MX341200B (es) | 2010-03-29 | 2016-08-11 | Ferring Bv | Composicion farmaceutica de disolucion rapida. |
| JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| US20120135050A1 (en) | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| BR112014005134A2 (pt) | 2011-09-16 | 2017-04-18 | Ferring Bv | composição farmacêutica de dissolução rápida |
| US20150306170A1 (en) | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
-
2011
- 2011-03-22 JO JOP/2011/0100A patent/JO3112B1/ar active
- 2011-03-28 DK DK11711526.1T patent/DK2552403T3/en active
- 2011-03-28 HU HUE11711526A patent/HUE026213T2/en unknown
- 2011-03-28 BR BR112012024428A patent/BR112012024428A2/pt not_active IP Right Cessation
- 2011-03-28 EP EP11711526.1A patent/EP2552403B1/en active Active
- 2011-03-28 TW TW100110569A patent/TWI513477B/zh not_active IP Right Cessation
- 2011-03-28 CA CA2793405A patent/CA2793405A1/en not_active Abandoned
- 2011-03-28 WO PCT/EP2011/054698 patent/WO2011120903A2/en active Application Filing
- 2011-03-28 ES ES11711526.1T patent/ES2553568T3/es active Active
- 2011-03-28 NZ NZ602441A patent/NZ602441A/en not_active IP Right Cessation
- 2011-03-28 MX MX2012011204A patent/MX2012011204A/es unknown
- 2011-03-28 AU AU2011234636A patent/AU2011234636B2/en not_active Ceased
- 2011-03-28 US US13/638,121 patent/US10086078B2/en active Active
- 2011-03-28 JP JP2013501779A patent/JP5907945B2/ja active Active
- 2011-03-28 KR KR1020127027215A patent/KR101725173B1/ko not_active Expired - Fee Related
- 2011-03-28 RU RU2012141141/15A patent/RU2566270C2/ru not_active IP Right Cessation
- 2011-03-28 PL PL11711526T patent/PL2552403T3/pl unknown
- 2011-03-28 CN CN2011800171635A patent/CN102821755A/zh active Pending
- 2011-03-28 PT PT117115261T patent/PT2552403E/pt unknown
- 2011-03-29 AR ARP110101023A patent/AR080736A1/es unknown
- 2011-03-29 SA SA111320317A patent/SA111320317B1/ar unknown
-
2012
- 2012-09-23 IL IL222086A patent/IL222086A/en not_active IP Right Cessation
- 2012-09-25 ZA ZA2012/07176A patent/ZA201207176B/en unknown
-
2018
- 2018-08-29 US US16/115,650 patent/US10512695B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL222086A (en) | 2017-01-31 |
| DK2552403T3 (en) | 2015-10-05 |
| US20130123180A1 (en) | 2013-05-16 |
| BR112012024428A2 (pt) | 2016-05-31 |
| EP2552403A2 (en) | 2013-02-06 |
| RU2566270C2 (ru) | 2015-10-20 |
| JO3112B1 (ar) | 2017-09-20 |
| WO2011120903A3 (en) | 2012-05-03 |
| AU2011234636B2 (en) | 2015-01-15 |
| KR101725173B1 (ko) | 2017-04-10 |
| JP2013523676A (ja) | 2013-06-17 |
| JP5907945B2 (ja) | 2016-04-26 |
| HK1181649A1 (en) | 2013-11-15 |
| RU2012141141A (ru) | 2014-05-10 |
| PT2552403E (pt) | 2015-10-30 |
| AU2011234636A1 (en) | 2012-10-11 |
| ZA201207176B (en) | 2013-05-29 |
| HUE026213T2 (en) | 2016-05-30 |
| CA2793405A1 (en) | 2011-10-06 |
| US20180369392A1 (en) | 2018-12-27 |
| SA111320317B1 (ar) | 2015-05-11 |
| US10086078B2 (en) | 2018-10-02 |
| MX2012011204A (es) | 2012-11-23 |
| KR20130008588A (ko) | 2013-01-22 |
| EP2552403B1 (en) | 2015-09-09 |
| US10512695B2 (en) | 2019-12-24 |
| ES2553568T3 (es) | 2015-12-10 |
| PL2552403T3 (pl) | 2016-01-29 |
| TWI513477B (zh) | 2015-12-21 |
| WO2011120903A2 (en) | 2011-10-06 |
| CN102821755A (zh) | 2012-12-12 |
| TW201138830A (en) | 2011-11-16 |
| NZ602441A (en) | 2014-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080736A1 (es) | Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla | |
| AR080735A1 (es) | Una composicion farmaceutica de disolucion rapida | |
| DOP2010000114A (es) | Producto de dispersion solida que contiene un compuesto a base de n-aril urea | |
| MX2015012433A (es) | Matriz de microestructura para suministro de agentes activos. | |
| MX383706B (es) | Composiciones de cenicriviroc y métodos para elaborarlas y usarlas. | |
| AR104212A1 (es) | Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina, métodos y usos de las mismas | |
| AR087871A1 (es) | Una composicion farmaceutica de rapida disolucion | |
| BR122019027412B8 (pt) | composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração | |
| MX2014015657A (es) | Composicion topica que comprende un polimero formador de pelicula para liberar un ingrediente activo a la piel. | |
| CO7131367A2 (es) | Formulación compuesta que comprende una tableta esferoidal de múltiples unidades (must) en cápsulada en cápsula dura y método para su preparación | |
| MX387266B (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos | |
| CL2013003161A1 (es) | Composicion farmaceutica en forma de microgranulos de disolucion rapida para administracion vaginal que comprende a) un farmaco vaginalmente activo, b) un excipiente polimerico, c) un alcohol de azucar, sacarido o una mezcla de los mismos; procedimiento de preparacion. | |
| AR093402A1 (es) | Producto de comicronizacion que comprende acetato de ulipristal | |
| CR11442A (es) | Producto de dispersion solida de drogas basadas en n-aril urea | |
| CO2017006958A2 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos | |
| PE20160850A1 (es) | Sistema multiparticulado para administrar drogas | |
| BR112015012453A8 (pt) | métodos e usos para sincronizar o tempo de ovulação e de inseminação em uma leitoa | |
| PE20160183A1 (es) | FORMULACION DE LIBERACION MODIFICADA DEL ACIDO (-)-(3aR,4S,7aR)-4-HIDROXI-4m-TOLILETINIL-OCTAHIDRO-INDOL-1-CARBOXILICO (AFQ056) | |
| CL2015001748A1 (es) | Formulaciones antiparasitarias transdermicas | |
| MX389554B (es) | Formulaciones antihelminticas veterinarias estables. | |
| MX2017015138A (es) | Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina. | |
| AR093922A1 (es) | Composicion farmaceutica que contiene telmisartan | |
| AR105503A1 (es) | Concentrado que contiene alprostadil | |
| CL2017002470A1 (es) | Proceso para obtener mezclas de polvo seco | |
| WO2013072770A3 (en) | Pharmaceutical formulations comprising atorvastatin and glimepiride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |